

Eugenia V Broude

List of Publications by Year in descending order

Source: <https://exaly.com/author-pdf/6788625/publications.pdf>

Version: 2024-02-01

46
papers

2,906
citations

304743

22
h-index

377865

34
g-index

47
all docs

47
docs citations

47
times ranked

4155
citing authors

#	ARTICLE	IF	CITATIONS
1	The Inhibition of CDK8/19 Mediator Kinases Prevents the Development of Resistance to EGFR-Targeting Drugs. <i>Cells</i> , 2021, 10, 144.	4.1	16
2	Abstract LB132: CDK8/19 inhibition overcomes in vitro and in vivo resistance to lapatinib in HER2+ breast cancer via STAT1 and STAT3. , 2021, , .		0
3	Inhibition of the Dead Box RNA Helicase 3 Prevents HIV-1 Tat and Cocaine-Induced Neurotoxicity by Targeting Microglia Activation. <i>Journal of NeuroImmune Pharmacology</i> , 2020, 15, 209-223.	4.1	11
4	Pharmacological inhibition of DEAD-Box RNA Helicase 3 attenuates stress granule assembly. <i>Biochemical Pharmacology</i> , 2020, 182, 114280.	4.4	19
5	CDK7 Inhibition Is Effective in all the Subtypes of Breast Cancer: Determinants of Response and Synergy with EGFR Inhibition. <i>Cells</i> , 2020, 9, 638.	4.1	24
6	Abstract 89: Role of CDK8 and CDK19 in STAT1 phosphorylation at serine 727. , 2020, , .		0
7	Identifying Cancers Impacted by CDK8/19. <i>Cells</i> , 2019, 8, 821.	4.1	31
8	Characterizing CDK8/19 Inhibitors through a NF κ B-Dependent Cell-Based Assay. <i>Cells</i> , 2019, 8, 1208.	4.1	11
9	Role of transcription-regulating kinase CDK8 in colon cancer metastasis. <i>Oncotarget</i> , 2019, 10, 622-623.	1.8	6
10	Structural insight into substrate and inhibitor discrimination by human P-glycoprotein. <i>Science</i> , 2019, 363, 753-756.	12.6	330
11	Systemic Toxicity Reported for CDK8/19 Inhibitors CCT251921 and MSC2530818 Is Not Due to Target Inhibition. <i>Cells</i> , 2019, 8, 1413.	4.1	33
12	Structure of a zosuquidar and UIC2-bound human-mouse chimeric ABCB1. <i>Proceedings of the National Academy of Sciences of the United States of America</i> , 2018, 115, E1973-E1982.	7.1	153
13	Inhibin Is a Novel Paracrine Factor for Tumor Angiogenesis and Metastasis. <i>Cancer Research</i> , 2018, 78, 2978-2989.	0.9	32
14	CDK8 Selectively Promotes the Growth of Colon Cancer Metastases in the Liver by Regulating Gene Expression of TIMP3 and Matrix Metalloproteinases. <i>Cancer Research</i> , 2018, 78, 6594-6606.	0.9	65
15	Mediator kinase CDK8/CDK19 drives YAP1-dependent BMP4-induced EMT in cancer. <i>Oncogene</i> , 2018, 37, 4792-4808.	5.9	49
16	Identification of novel cancer therapeutic targets using a designed and pooled shRNA library screen. <i>Scientific Reports</i> , 2017, 7, 43023.	3.3	33
17	CDK8/19 Mediator kinases potentiate induction of transcription by NF κ B. <i>Proceedings of the National Academy of Sciences of the United States of America</i> , 2017, 114, 10208-10213.	7.1	89
18	Cellular Model of p21-Induced Senescence. <i>Methods in Molecular Biology</i> , 2017, 1534, 31-39.	0.9	39

#	ARTICLE	IF	CITATIONS
19	Inhibition of CDK8 mediator kinase suppresses estrogen dependent transcription and the growth of estrogen receptor positive breast cancer. <i>Oncotarget</i> , 2017, 8, 12558-12575.	1.8	92
20	Abstract 1512: Functional characterization of novel transcription-regulating cancer drug targets, CDK8 and CDK19, using CRISPR/Cas9 knockout and a highly selective CDK8/19 kinase inhibitor. , 2017, , .		0
21	Abstract 4896: Role of CDK8 in colon cancer hepatic metastasis. , 2017, , .		1
22	Identification of novel genes that regulate androgen receptor signaling and growth of androgen-deprived prostate cancer cells. <i>Oncotarget</i> , 2015, 6, 13088-13104.	1.8	18
23	Expression of CDK8 and CDK8-interacting Genes as Potential Biomarkers in Breast Cancer. <i>Current Cancer Drug Targets</i> , 2015, 15, 739-749.	1.6	67
24	Abstract PR08: Targeting tumor microenvironment with selective small-molecule inhibitors of CDK8/19. , 2015, , .		1
25	Abstract P4-15-13: CDK8 inhibition potentiates anti-ER and anti-HER2 therapies in breast cancer. , 2015, , .		0
26	Abstract 5459: Overcoming resistance to HER2-targeting drugs using CDK8 inhibitors. , 2015, , .		0
27	Abstract 4879: Targeting the seed and the soil of cancers with selective small-molecule inhibitors of CDK8/19: Chemopotentiating, chemopreventive, anti-invasive and anti-metastatic activities. <i>Cancer Research</i> , 2014, 74, 4879-4879.	0.9	3
28	Abstract 2101: Role of CDK8 in estrogen receptor signaling in breast cancers. , 2014, , .		0
29	Abstract 4883: CDK8: A new druggable mediator of NF κ B activity. , 2014, , .		0
30	Cyclin-dependent kinase 8 mediates chemotherapy-induced tumor-promoting paracrine activities. <i>Proceedings of the National Academy of Sciences of the United States of America</i> , 2012, 109, 13799-13804.	7.1	146
31	Abstract 1820: CDK3: A novel tumor-selective drug target involved in AP1 activation and transcriptional damage response. <i>Cancer Research</i> , 2012, 72, 1820-1820.	0.9	1
32	Effects of conditional depletion of topoisomerase II on cell cycle progression in mammalian cells. <i>Cell Cycle</i> , 2011, 10, 3505-3514.	2.6	31
33	Tumor-specific silencing of COP22 gene encoding coatomer protein complex subunit β 2 renders tumor cells dependent on its paralogous gene COP21. <i>Proceedings of the National Academy of Sciences of the United States of America</i> , 2011, 108, 12449-12454.	7.1	40
34	Abstract LB-401: The chemosensitizing properties of iniparib in combination with DNA-damaging agents in the MDA-MB-468 (triple-negative breast cancer (TNBC) cell line. , 2011, , .		5
35	Function-based gene identification using enzymatically generated normalized shRNA library and massive parallel sequencing. <i>Proceedings of the National Academy of Sciences of the United States of America</i> , 2010, 107, 7377-7382.	7.1	15
36	EXPRESSION OF SENESCENCE-ASSOCIATED GROWTH REGULATORY PROTEINS IN HUMAN PROSTATE CANCER. <i>Journal of Urology</i> , 2009, 181, 514-514.	0.4	0

#	ARTICLE	IF	CITATIONS
37	THERAPY-INDUCED SENESENCE RESPONSE AND DIFFERENTIAL GENE EXPRESSION IN PROSTATE CANCER CELLS WITH VARIABLE METASTATIC POTENTIAL. <i>Journal of Urology</i> , 2008, 179, 191-192.	0.4	1
38	Mitotic Catastrophe in Cancer Therapy. , 2008, , 307-320.		5
39	p21 (CDKN1A) is a Negative Regulator of p53 Stability. <i>Cell Cycle</i> , 2007, 6, 1467-1470.	2.6	53
40	Notch inhibition in Kaposi's sarcoma tumor cells leads to mitotic catastrophe through nuclear factor- κ B signaling. <i>Molecular Cancer Therapeutics</i> , 2007, 6, 1983-1992.	4.1	36
41	Molecular determinants of terminal growth arrest induced in tumor cells by a chemotherapeutic agent. <i>Proceedings of the National Academy of Sciences of the United States of America</i> , 2002, 99, 389-394.	7.1	272
42	If not apoptosis, then what? Treatment-induced senescence and mitotic catastrophe in tumor cells. <i>Drug Resistance Updates</i> , 2001, 4, 303-313.	14.4	625
43	p21Waf1/Cip1/Sdi1-induced growth arrest is associated with depletion of mitosis-control proteins and leads to abnormal mitosis and endoreduplication in recovering cells. <i>Oncogene</i> , 2000, 19, 2165-2170.	5.9	171
44	Role of p53 and p21waf1/cip1 in senescence-like terminal proliferation arrest induced in human tumor cells by chemotherapeutic drugs. <i>Oncogene</i> , 1999, 18, 4808-4818.	5.9	352
45	A Combination of Genetic Suppressor Elements Produces Resistance to Drugs Inhibiting DNA Replication. <i>Somatic Cell and Molecular Genetics</i> , 1999, 25, 9-26.	0.7	19
46	Down-Regulation of Cyclin F Levels during Nerve Growth Factor-Induced Differentiation of PC12 Cells. <i>Experimental Cell Research</i> , 1996, 227, 203-207.	2.6	8